RECEIVED
CENTRAL FAX CENTER

JUN 0 6 2007

| | | | |
|---|---|---|---|
| **In re United States Patent Application of:** | | **Docket No.:** | **4258-120** |
| **Applicants:** | **MASCARENHAS SARAIVA, Maria Joao, et al.** | **Examiner:** | **S. Kumar** |
| **Application No.:** | **10/574,875** | | |
| **Date Filed:** | **April 6, 2006** | | |
| **Title:** | **COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS** | **Customer No.:** | **23448** |

**Via facsimile To Examiner S. Kumar**
**(571) 273-0640**

## PROPOSED AMENDMENT OF CLAIMS

Please cancel claims 7-9, and amend claims 2-6, in the following listing of claims 1-9 of the application:

1. (Original) A compound of structural formula (I):



(I)

in which

$R_1$ is a $-NR_aR_b$ group, where $R_a$ and $R_b$, independently, are a hydrogen atom or a $C_1$-$C_6$ alkyl group; $-OR_C$ group, where $R_C$ is a hydrogen atom or a $C_1$-$C_6$ alkyl group; a glycosyl; a $C_1$-$C_6$ polyhydroxyalkyl; or a $-NH-CH(R_d)-COOR_e$ group, where $R_d$ is a

side chain of one of the 20 natural alpha-amino acids in either of their two enantiomerically pure forms L or D, and $R_e$ is a hydrogen atom or a $C_1$-$C_6$ alkyl group; and

$R_2$ is a hydrogen atom, a $C_1$-$C_6$ alkyl group, a glycosyl; a $C_1$-$C_6$ polyhydroxyalkyl; –C(=O)-$R_f$ group, where $R_f$ is a $C_1$-$C_6$ alkyl group; or a -$CH_2$-COO-$R_g$ group, where $R_g$ is a hydrogen atom or a $C_1$-$C_6$ alkyl group;

and pharmaceutically acceptable salts thereof.

2. (Currently amended) A compound according to claim 1, ~~characterised in that~~ wherein $R_1$ is selected from: OH, $NH_2$, OMe, OEt, or a $CH(R_d)$-$COR_e$ group, where $R_d$ is the side chain of glycine, alanine, leucine, valine, aspartic acid or asparagine and where $R_e$ is H or a $C_1$-$C_6$ alkyl group; and $R_2$ is selected from: H, Me, glycosyl, a –C(=O)-$R_f$ group, where $R_f$ is a Me, Et, t-Bu group; or a -$CH_2$-COO-$R_g$ group, where $R_g$ is a hydrogen atom or a t-Bu group.

3. (Currently amended) A compound according to claim 1, ~~characterised in that it is~~ selected from the ~~following compounds~~ group consisting of:

[1] 5-(2,4-difluorophenyl)-3-iodo-salicylic acid;
[2] ethyl 5-(2,4-difluorophenyl)-3-iodo-salicylate;
[3] methyl 5-(2,4-difluorophenyl)-3-iodo-salicylate;
[4] 5-(2,4-difluorophenyl)-3-iodo-salicylamide;
[5] tert-butyl [2-aminocarbonyl-4-(2,4-difluorophenyl)-6-iodo-phenoxy]-acetate;
[6] [2-aminocarbonyl-4-(2,4-difluorophenyl)-6-iodo-phenoxy]acetic acid;
[7] 5-(2,4-difluorophenyl)-3-iodo-salicylic acid 1-O-β-glycoside;
[8] ethyl 2',4'-difluoro-4-methoxy-5-iodo-[1,1']biphenyl-3-carboxylate;
[9] 2',4'-difluoro-4-methoxy-5-iodo-[1,1']biphenyl-3-carboxylic acid;
[10] ethyl 2',4'-difluoro-4-acetyloxy-5-iodo-[1,1']biphenyl-3-carboxylate;
[11] 2',4'-difluoro-4-(*t*-butylcarbonyloxy)-5-iodo-[1,1']biphenyl-3-carboxylic acid;
[12] 2',4'-difluoro-4-(ethylcarbonyloxy)-5-iodo-[1,1']biphenyl-3-carboxylic acid;
[13] ethyl ester of N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]glycine;
[14] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]glycine;
[15] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]alanine;
[16] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]leucine;
[17] N-[5-(2,4-difluorophenyl)-3-iodo-salicyloyl]serine;